Related Experiment Video
Updated: Nov 27, 2025

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
News on infantile haemangioma. Part 1: clinical course and pathomechanism
H De Leye1, J Saerens1, S R Janmohamed1
1Department of Dermatology, Universitair Ziekenhuis Brussel (UZB), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Abstract:
Currently, there is no doubt that the first choice of treatment for alarming infantile haemangiomas (IHs) is oral beta-blockers. However, research in this field remains active, as the pathogenesis of IH is still not completely elucidated. Furthermore, there are different approaches to the management of IHs with beta-blockers. In Part 1 of this review we will discuss the state-of-the-art evidence for IH with regard to (i) the definition, epidemiology, course, risk factors and sequelae, and (ii) the pathogenesis, focusing on genetic studies. This review will update the reader on the latest developments in the pathogenesis of IH. Furthermore, we hope this review will give more insight into risk factors and sequelae of IH, thereby contributing to better decisions in the clinical management of patients with IH. The therapy and evaluation of IHs will be discussed in Part 2 of this review.
Related Concept Videos
Mechanism of Angiogenesis
Development of Blood Vessels
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
Regulation of Angiogenesis and Blood Supply
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Hematopoiesis
Pharmacokinetics in Pediatric Patients: Drug Metabolism

